Biotechnology drugmaker AbbVie Inc. filed a lawsuit seeking to block Amgen Inc. from selling a copy of the arthritis medicine Humira, its top seller.
Amgen’s proposed copy would infringe at least 10 patents, AbbVie said as it reserved the right to assert as many as 51 other patents. It’s seeking a court order to prevent Amgen from selling a copy, known as a biosimilar, of the biotech drug.
Amgen’s proposed copy would infringe at least 10 patents, AbbVie said as it reserved the right to assert as many as 51 other patents. It’s seeking a court order to prevent Amgen from selling a copy, known as a biosimilar, of the biotech drug.
